恒瑞医药：SHR-4375注射液等六款产品临床试验获批

Core Viewpoint - Heng Rui Medicine announced the approval of multiple clinical trial applications for new drug candidates by the National Medical Products Administration, indicating a significant step forward in its research and development efforts [1] Group 1: Clinical Trial Approvals - The company and its subsidiaries received approval for clinical trials of SHR-4375 injection, Adalimumab injection, SHR-8068 injection, Bevacizumab injection, HRS-4642 injection, and SHR-9839 (sc) injection [1] - The approved clinical trials are set to commence in the near future, reflecting the company's ongoing commitment to expanding its product pipeline [1]